Hypertension in malignancy-an underappreciated problem

Oncotarget
Jolanta MałyszkoJacek Małyszko

Abstract

Hypertension is one of the most common comorbidities in cancer patients with malignancy, in particular, in the elderly. On the other hand, hypertension is a long-term consequence of antineoplastic treatment, including both chemotherapy and targeted agents. Several chemotherapeutics and targeted drugs may be responsible for development or worsening of the hypertension. The most common side effect of anti-VEGF (vascular endothelial growth factor) treatment is hypertension. However, pathogenesis of hypertension in patients receiving this therapy appears to be associated with multiple pathways and is not yet fully understood. Development of hypertension was associated with improved antitumor efficacy in patients treated with anti-antiangiogenic drugs in some but not in all studies. Drugs used commonly as adjuvants such as steroids, erythropoietin stimulating agents etc, may also cause rise in blood pressure or exacerbate preexisiting hypertension. Hypotensive therapy is crucial to manage hypertension during certain antineoplastic treatment. The choice and dose of antihypertensive drugs depend upon the presence of organ dysfunction, comorbidities, and/or adverse effects. In addition, severity of the hypertension and the urgency of b...Continue Reading

References

Nov 1, 1979·Annals of Internal Medicine·D D Von HoffF M Muggia
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P TothillJ F Smyth
Mar 19, 2003·Circulation·Timothy D HenryUNKNOWN VIVA Investigators
Apr 14, 2004·Journal of Internal Medicine·Peter Carmeliet
May 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·O HequetB Coiffier
May 27, 2004·JAMA : the Journal of the American Medical Association·Jay F PiccirilloEdward L Spitznagel
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Mar 22, 2005·Experimental Physiology·Paolo Madeddu
Apr 26, 2005·BMJ : British Medical Journal·Josie M M EvansAndrew D Morris
Jul 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H SagstuenR M Bremnes
Oct 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Justin D FloydMichael C Perry
Feb 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Domenic A Sica
Feb 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria Luisa VeronesePeter J O'Dwyer
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Jun 26, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O RixeH Izzedine
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary C PinderSharon H Giordano
Aug 10, 2007·Current Hypertension Reports·Manish Jain, Raymond R Townsend
Dec 18, 2007·Lancet·Heikki Joensuu
Dec 18, 2007·Lancet·Tammy F ChuMing Hui Chen
Jan 4, 2008·The New England Journal of Medicine·Michel AziziStéphane Oudard
Mar 14, 2008·The New England Journal of Medicine·Vera EreminaSusan E Quaggin
May 23, 2008·Gynecologic Oncology·Walter H GotliebIlan Bruchim
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph R CarverJohn H Glick
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dawn L HershmanJudith S Jacobson
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nilofer S AzadElise C Kohn
Oct 3, 2008·Bulletin du cancer·Marie SireAlain Ravaud
Oct 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manuela SchmidingerHerwig Schmidinger
Oct 10, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ScartozziS Cascinu
Nov 29, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Simon K WinnJames E Marsh
Dec 6, 2008·International Journal of Cancer. Journal International Du Cancer·Dejana BraithwaiteLaura Esserman
Jan 20, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H IzzedineJ P Spano
Feb 13, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P BonoH Joensuu
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Darren R FeldmanRobert J Motzer
Apr 1, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Edgar J RollemanMichiel G H Betjes
May 29, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G Di LorenzoS De Placido
Sep 24, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael L MaitlandMark J Ratain
Nov 18, 2009·Diabetes Care·Gijs W D LandmanHenk J G Bilo
Nov 19, 2009·Journal of Gastrointestinal Cancer·Rebekah Ryanne WuAiwu R He

❮ Previous
Next ❯

Citations

Jan 10, 2019·Journal of Hypertension·Vasiliki KatsiDimitrios Tousoulis
Aug 5, 2020·Journal of Human Hypertension·Hani EssaGregory Y H Lip
Nov 7, 2018·World Journal of Clinical Cases·Amitabha Ray
Jun 3, 2021·Journal of Hypertension·Ganessan KichenadasseAshley M Hopkins
Aug 4, 2021·Current Oncology Reports·Maude SestierDarryl Leong

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Clinical Trials Mentioned

NCT01206062

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Gwenalyn Garcia, Jean Paul Atallah
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
U Tirelli, S Monfardini
© 2022 Meta ULC. All rights reserved